PEPTIDE COMPARISON

Tesamorelin vs Ipamorelin

An approved GHRH analog compared with an unapproved ghrelin-receptor agonist.

QUICK ANSWER

Tesamorelin vs Ipamorelin: the main difference.

Tesamorelin and ipamorelin act through different receptors and have very different evidence maturity. Tesamorelin’s approval is narrow; ipamorelin’s endocrine activity is not proof of a clinical benefit.

Decision field	Tesamorelin	Ipamorelin
Human research	Large indication-specific trials	Early pharmacology and limited clinical studies
Primary research	HIV-associated visceral fat	GH secretion and postoperative ileus
FDA status	Approved for one narrow indication	No approved product
Mechanism	Stimulates the GHRH receptor	Ghrelin-receptor agonist / secretagogue
Evidence confidence	High only for the labeled use	Low for wellness-market claims

SOURCES

Tesamorelin vs Ipamorelin sources.

FDA / 2025EGRIFTA WR prescribing informationU.S. FDA Human trial / 2010Pooled analysis of two Phase 3 tesamorelin trialsPubMed WADA / 20262026 Prohibited ListWorld Anti-Doping Agency FDA / 2024–2026FDA briefing and compounding safety concerns for ipamorelinU.S. FDA

Tesamorelin vs Ipamorelin: the main difference.

Tesamorelin vs Ipamorelin sources.

Questions related to Tesamorelin vs Ipamorelin.

Compare the next decision.